Fused imidazole and pyrazole derivatives as modulators of TNF activity
US9868749B2 · kind B2 · utility
13Cited by
1References
7Claims
0Family size
Assignee
Inventors
- Rikki Peter Alexander
- Jonathan Mark Bentley
- Gareth Neil Brace
- Daniel Christopher Brookings
- Prafulkumar Tulshibhai Chovatia
- Hervé Jean Claude Deboves
- Craig Johnstone
- Elizabeth Pearl Jones
- Boris Kroeplien
- Fabien Claude Lecomte
- James Madden
- Craig Andrew Miller
- John Robert Porter
- Matthew Duncan Selby
- Michael Alan Shaw
- Darshan Gunvant Vaidya
- Ian Yule
Key dates
| Filing date | Dec 8, 2014 |
| Grant date | Jan 16, 2018 |
| Priority date | — |
| Expiry date | Dec 8, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A series of substituted benzimidazole, imidazo[1,2-a]pyridine and pyrazolo[1,5-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.